Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mineralys Therapeutics, Inc. (Nasdaq: MLYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor, through clinical development. As a clinical-stage biopharmaceutical company focused on hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-driven diseases, Mineralys uses SEC filings to report financial results, capital-raising activities and other material events.
Current and prospective investors can review Form 8-K filings where Mineralys reports quarterly financial results and corporate updates, as well as transactions such as underwritten public offerings of common stock and changes to at-the-market equity programs. These documents often reference the company’s clinical progress with lorundrostat, including pivotal trials like Launch-HTN and Advance-HTN, Phase 2 programs such as Explore-CKD and Explore-OSA, and steps toward a potential New Drug Application (NDA) with the U.S. Food and Drug Administration.
Over time, the filings set is expected to include annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that elaborate on risk factors, liquidity, research and development spending, and the company’s dependence on the success of lorundrostat and key licensing arrangements. Investors may also monitor registration statements and prospectus supplements related to equity offerings, as reflected in referenced Form S-3 filings.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight key points, such as trial-related disclosures, financing terms and forward-looking statements. Real-time updates from EDGAR, combined with tools to track items like material events and offering details, help users quickly understand how Mineralys Therapeutics’ regulatory and financial reporting aligns with its clinical and regulatory strategy for lorundrostat.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a small, pre-planned insider transaction. On April 17, 2026, he sold 416 shares of common stock in an open-market sale at $31.33 per share and exercised stock options for 416 shares at $15.44 per share. These trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly owned 69,792 shares of common stock and held 4,584 stock options as reported in this filing.
Mineralys Therapeutics submitted a Form 144 notifying the sale of 416 shares of Common Stock on 04/17/2026 via a broker-assisted cashless exercise of employee stock options. The filing also lists multiple recent open-market dispositions by David Rodman over the prior three months, with individual sales such as 14,058 shares on 04/13/2026 ($373,086.81) and 6,348 shares on 04/15/2026 ($175,585.68).
Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option exercises and share sales in the company’s stock. On April 13, he exercised stock options covering a total of 14,058 shares of Common Stock at strike prices of $1.08, $10.20, and $14.25 per share. That same day, he conducted an open-market sale of 14,058 shares of Common Stock at a weighted-average price of $26.5391 per share. On April 15, he completed a second open-market sale of 6,348 shares at $27.66 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 69,792 shares of Common Stock.
Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported an open-market sale of 15,730 shares of common stock on April 13, 2026 at a weighted-average price of $26.8264 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Following this sale, Congleton directly holds 689,321 shares of Mineralys common stock, indicating that the transaction covers only a portion of his overall equity position. The shares were sold in multiple trades at prices ranging from $26.81 to $26.96.
David Rodman filed a Form 144 reporting proposed and recent sales of common stock. The notice lists a proposed sale of 6,348 shares tied to an exercise of employee stock options on 04/14/2025. The filing also records multiple completed sales between 01/09/2026 and 04/13/2026, including 14,058 shares sold on 04/13/2026 for $373,086.81.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.
These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly holds 76,140 shares of Mineralys Therapeutics common stock.
Jon Congleton reported Rule 144 transactions in Mineralys Therapeutics common stock, including sales of 16,236 shares on 01/12/2026 for $529,639.51 and 75,000 shares on 03/31/2026 for $1,970,520.69. The filing also shows a vesting of 15,730 restricted share units on 04/10/2026 granted under the issuer's equity compensation plan.
Mineralys Therapeutics, Inc. affiliate submitted a Form 144 notice reporting proposed sales of 14,058 shares of common stock for $373,086.81 to occur on 04/13/2026 via a broker-assisted cashless exercise. The filing also lists multiple open-market dispositions by David Rodman totaling repeated small sales across January–April 2026, including a 14,058-share sale on 03/13/2026 for $369,225.07.
Mineralys Therapeutics, Inc. filing under Rule 144 discloses an intended sale of 2,170 shares of Common Stock on 04/09/2026 tied to an exercise of employee stock options executed as a broker-assisted cashless exercise. The filing also lists multiple recent open-market dispositions by David Rodman, including sales on 01/14/2026 (11,367 shares for $370,645.39) and 03/13/2026 (14,058 shares for $369,225.07).
The notice is a typical Rule 144 transaction report describing specific shares to be sold and a sequence of recent sales; cash‑flow treatment and remaining holdings are not stated in the excerpt.